Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The evaluation content is largely consistent with the label for the boxed warning linkage (semaglutide and thyroid C-cell tumors, and contraindications in MTC/MEN 2). However, several claims about product formulation (once-weekly injection) and about Ozempic vs Wegovy using semaglutide as shared active ingredient are not supported by the provided FDA label excerpts and cannot be verified from the text supplied.
Category Scores
Accurate Statements
WARNING: RISK OF THYROID C-CELL TUMORS (for OZEMPIC/semaglutide).
Section 5.1 states semaglutide causes dose- and duration-dependent increases in thyroid C-cell tumors in mice and rats and notes unknown human relevance; Boxed Warning referenced.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Section 4 Contraindications includes personal/family history of MTC or MEN 2; Section 5.1 links contraindication to Warnings and Precautions (5.1).
The label includes counseling that semaglutide causes thyroid C-cell tumors in rodents and the human relevance has not been determined.
Section 17 Patient Counseling Information (Risk of Thyroid C-cell Tumors) states semaglutide causes thyroid C-cell tumors in rodents and human relevance has not been determined.
Unsupported Statements
Ozempic is supplied as a once-weekly injection.
The supplied label excerpts do not include dosing frequency/administration schedule language verifying once-weekly supply for Ozempic.
Ozempic and Wegovy both use semaglutide as the active ingredient.
No Wegovy label text was provided in the prompt; the provided excerpts are for Ozempic only.
The shared active ingredient between Ozempic and Wegovy is semaglutide.
Same issue: Wegovy information/label text is not provided, so shared active ingredient cannot be verified from the supplied prescribing information.
Ozempic and Wegovy are different products.
The prompt provides no label text or prescribing information basis for comparing product identity between Ozempic and Wegovy.
The inactive formulation details for Ozempic are not specified in the provided information.
The prompt does not provide the full Ozempic label; the statement is about completeness of the 'provided information' rather than label support and is not verifiable against the supplied excerpts.
The complete list of active and inactive ingredients is typically printed in the "inactive ingredients" section of the product’s prescribing information and on the packaging insert for the specific product/strength.
This is a general statement about typical labeling/packaging content not supported by the provided Ozempic excerpts.
The full excipient list is not included in the provided information.
While it may be true for the excerpts shown, the provided excerpts are incomplete and the prompt does not include the full label to confirm omission; therefore the claim cannot be verified as a label-mismatch or label-supported fact.
Contradictions
Important Omissions
Ozempic-specific dosage and administration details (including dosing frequency) are not provided in the evaluation content, despite a claim asserting once-weekly injection.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The core boxed warning linkage and contraindication for MTC/MEN 2 are supported by the provided Ozempic label excerpts. However, unsupported assertions about product formulation and Ozempic administration frequency could lead to misunderstanding if relied upon; Wegovy comparisons are not verifiable from the provided Ozempic label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims (e.g., once-weekly supply and Ozempic vs Wegovy semaglutide/identity) are not supported by the provided Ozempic prescribing information excerpts and/or lack Wegovy label text.
Suggested Improvement
Limit claims to what is explicitly supported by the provided Ozempic label sections (e.g., semaglutide and thyroid C-cell tumor boxed warning, contraindication in MTC/MEN 2, and patient counseling). Remove or reframe unverifiable product-comparison and administration-frequency statements unless the corresponding FDA label text for Wegovy and Ozempic dosing schedule is provided.